
Bristol Myers drug fails main goal in cancer-linked anemia trial
The study did not achieve statistically significant results in helping patients with myelofibrosis become free from red blood cell transfusions for any 12-week period during the first 24 weeks of treatment.
The miss could signal long-term challenges for the company as future revenues rely on expanding the use of key drugs, Raymond James analysts said.
They noted several missed opportunities for broader approvals, including Sotyktu in ulcerative colitis and Crohn's, Camzyos in heart disease, Opdualag in early-stage melanoma, and Cobenfy in schizophrenia.
The company, however, remained upbeat about the drug's prospects and said more patients receiving Reblozyl saw a reduction in the number of transfusions needed and an increase in hemoglobin levels, a key measure of anemia. The side effects seen in the trial were similar to those previously reported for Reblozyl.
"It is promising to see that Reblozyl led to clinically relevant improvement of anemia for patients with myelofibrosis," said Anne Kerber, head of hematology, oncology, and cell therapy at Bristol Myers.
Reblozyl is already approved for certain types of anemia related to other blood disorders, including myelodysplastic syndromes and beta-thalassemia. Bristol Myers recorded $1.77 billion in global sales of Reblozyl in 2024.
The late-stage trial in myelofibrosis patients tested Reblozyl with a Janus kinase inhibitor drug, a class of medicines that works by slowing down the immune system.
Myelofibrosis is a type of cancer that scars the bone marrow, inhibiting production of healthy blood cells.
Reblozyl's failure in the trial might be positive for Disc Medicine (IRON.O), opens new tab, as investors might look favorably at its hepcidin portfolio, given the strength of data and limited treatment options, BMO Capital Markets analysts said.
Shares of Disc Medicine rose 4%, while Bristol Myers slipped 1% in morning trading.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
16 minutes ago
- The Independent
Donald Trump announces trade agreement with the European Union
Donald Trump announced a trade agreement with the European Union. The agreement will cut tariff rates on imports from the EU to 15 per cent. Conversely, US exports to the EU will become tariff-free under the new arrangement. Trump made the announcement alongside European Commission president Ursula von der Leyen at his Turnberry golf course in Scotland. Further details regarding the agreement were not immediately released by the White House.


Reuters
17 minutes ago
- Reuters
Boeing's contract offer rejected by union members
July 27 (Reuters) - Union members who assemble Boeing's (BA.N), opens new tab fighter jets in the St. Louis area have "overwhelmingly voted" to reject the company's contract offer on Sunday. Boeing's proposal, which was sent on Tuesday to more than 3,200 members of the International Association of Machinists and Aerospace Workers (IAM) District 837, included a 20% general wage increase over four years and a $5,000 ratification bonus, as well as more vacation time and sick leave. "The proposal from Boeing Defense fell short of addressing the priorities and sacrifices of the skilled IAM Union workforce," the IAM union said. Boeing did not immediately respond to a Reuters' request for a comment. The current contract expires on Sunday following which there is a seven-day cooling off period before a strike would begin, the union added. Boeing's defense division is expanding manufacturing facilities in the St. Louis area for the new U.S. Air Force fighter, the F-47, after it won the contract earlier this year.


Daily Mail
17 minutes ago
- Daily Mail
Los Angeles Chargers star Rashawn Slater set to sign all-time record NFL contract
The Los Angeles Chargers have reportedly reached an agreement on a contract extension with left tackle Rashawn Slater. The 26-year-old is reportedly set to sign a four-year, $114 million contract extension that includes a record $92 million guaranteed, according to Adam Schefter. The deal is set to make Slater the highest-paid offensive lineman in NFL history. More to follow.